Cessatech is developing CT001, a non-invasive analgesic nasal spray for children aged 1-17 experiencing acute pain. This needle-free formulation uses a combination of established analgesics for faster onset and improved safety compared to traditional methods.
Funding
$732.7K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Pediatric patients experiencing acute pain often lack effective, non-invasive analgesic options, leading to reliance on intravenous administration which can be painful and difficult to manage. This situation contributes to significant unmet needs in pediatric pain management, with a substantial percentage of children undergoing painful procedures receiving inadequate pain relief.
Solution
Cessatech is developing CT001, a non-invasive analgesic nasal spray designed for children aged 1-17 experiencing acute pain or pain related to medical procedures. CT001 utilizes a fixed combination of two established analgesics, previously approved for intravenous use in adults, to offer a faster onset of action and mitigate potential side effects like sedation and respiratory depression. The product has successfully completed a Phase II clinical trial and is finalizing its late-stage clinical program, demonstrating a favorable safety and tolerability profile and significant pain reduction in pediatric subjects. This approach aims to provide a child-friendly, needle-free alternative to current pain management modalities.
Target Audience
The primary target audience includes pediatricians, anesthesiologists, emergency department physicians, and hospital administrators involved in pain management for children aged 1-17.
Features
- Intranasal analgesic nasal spray formulation for pediatric acute pain management.
- Utilizes a fixed combination of two well-established analgesics with proven efficacy in adults.
- Designed for rapid onset of action and avoidance of undesirable side effects common with other analgesic routes.
- Completed a Phase II clinical trial in 50 pediatric patients, with 94% expressing preference for the treatment over existing alternatives.
- Finalizing late-stage clinical development, including a Paediatric Study 0202 which has met its primary endpoint for pain relief and demonstrated a favorable safety profile.
- Received a positive Notified Body Opinion under the Medical Devices Regulation (MDR) for CT001, confirming technical documentation adequacy for General Safety and Performance Requirements.
- Addresses the unmet need for needle-free, effective pain relief in children undergoing medical procedures.